Cargando…

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient

Detalles Bibliográficos
Autores principales:	Negri, T, Casieri, P, Miselli, F, Orsenigo, M, Piacenza, C, Stacchiotti, S, Bidoli, P, Casali, P G, Pierotti, M A, Tamborini, E, Pilotti, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360227/ https://www.ncbi.nlm.nih.gov/pubmed/17213828 http://dx.doi.org/10.1038/sj.bjc.6603542

Ejemplares similares

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1
por: Tefferi, Ayalew
Publicado: (2009)

Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors
por: Pantaleo, Maria A, et al.
Publicado: (2014)

c-KIT and c-KIT ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases
por: Tamborini, E, et al.
Publicado: (2001)

Pdgfra and Pdgfrb Genetically Interact in the Murine Neural Crest Cell Lineage to Regulate Migration and Proliferation
por: Mo, Julia, et al.
Publicado: (2020)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis
por: Welsh, Seth J., et al.
Publicado: (2017)

Data on quantification of signaling pathways activated by KIT and PDGFRA mutants
por: Bahlawane, Christelle, et al.
Publicado: (2016)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST
por: Urbini, Milena, et al.
Publicado: (2019)

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
por: Lassus, H, et al.
Publicado: (2004)

Malignant melanoma of the conjunctiva: a case report with examination of KIT and PDGFRA
por: Terada, Tadashi
Publicado: (2012)

Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations
por: Eliyakin, Nuket, et al.
Publicado: (2015)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance
por: Carlotto, Bianca Soares, et al.
Publicado: (2023)

Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
por: Rossi, Sabrina, et al.
Publicado: (2016)

Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs)
por: Morini, Maria, et al.
Publicado: (2022)

Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma
por: Tateishi, Kensuke, et al.
Publicado: (2023)

P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN-EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND JAK REARRANGEMENT
por: Zhang, Y., et al.
Publicado: (2022)

Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST
por: Astolfi, Annalisa, et al.
Publicado: (2020)

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
por: Ip, Carman K. M., et al.
Publicado: (2018)

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting
por: Maleddu, Alessandra, et al.
Publicado: (2011)

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
por: Merkelbach-Bruse, Sabine, et al.
Publicado: (2010)

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis
por: Zong, Liang, et al.
Publicado: (2014)

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
por: Baskin, Yasemin, et al.
Publicado: (2016)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib
por: Stacchiotti, Silvia, et al.
Publicado: (2012)

Corneal Vascularization Associated With a Novel PDGFRB Variant
por: Gladkauskas, Titas, et al.
Publicado: (2023)

Erratum to: The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021)

SYT-SSX fusion genes and prognosis in synovial sarcoma
por: Mezzelani, A, et al.
Publicado: (2001)

The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma
por: Pilotti, S, et al.
Publicado: (2000)

Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations
por: Rizzo, Francesca Maria, et al.
Publicado: (2016)

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
por: Bauer, Sebastian, et al.
Publicado: (2021)

HGG-19. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS
por: Trissal, Maria, et al.
Publicado: (2023)

Identification of a novel spliced variant of the SYT gene expressed in normal tissues and in synovial sarcoma
por: Tamborini, E, et al.
Publicado: (2001)

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
por: Schroeder, Brett A., et al.
Publicado: (2020)

Recurrent PDGFRB mutations in unicentric Castleman disease
por: Li, Zhaoming, et al.
Publicado: (2019)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6euf0oo1m32dh47bihf3kjd24n